id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-295123-x2gxgave	Zhou, Wei	Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia	2020-02-21		.txt	text/plain	1705	77	36	However, according to the Chinese government's daily report, 13.2-21.3% of patients with 2019-nCoV infection developed into severe or fatal illness (Fig. S1a ), which is characterized by the rapid development to acute respiratory distress syndrome (ARDS) or septic shock. On February 7, 2020, the China's National Health Commission released the fifth trial version of Diagnosis and Treatment Scheme for Pneumonitis with 2019-nCoV Infection, and provided a systematic treatment strategy for severe cases. Some scholars may not support the corticosteroids treatment for novel coronavirus pneumonia (NCP), because observational studies and systematic reviews have indicated inconclusive clinical evidence on the effect of corticosteroids therapy for viral pneumonias (such as SARS, MERS and H1N1). Evidently, all these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications (such as refractory ARDS, sepsis or septic shock) according to the recommended guidelines.	./cache/cord-295123-x2gxgave.txt	./txt/cord-295123-x2gxgave.txt